Floatz logo

18f-op-801

Parkinson Disease (PD)

Ashvattha Therapeutics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

255 Active assets in the Parkinson Disease (PD) cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Pardoprunox
Abbott Products
Phase 3BBB
Istradefylline
Georgetown University
Phase 4BBB

View all 50 →

Same molecule, other indications

18f-op-801 is also rated in:

Alzheimer diseaseDormant
CC
Indicative ·
47 / 100
View asset →
multiple sclerosisDormant
CC
Indicative ·
47 / 100
View asset →
amyotrophic lateral sclerosisDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →